Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

Relationship between IL-10 expression and prognosis in patients with primary breast cancer

Authors: Ying Li, Ping Gao, Junlan Yang, Haiming Yu, Yanyun Zhu, Wen Si

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

This retrospective study was designed to investigate the relationship between the expression of IL-10, CD4, CD8, and FOXP3 and clinicopathological features and prognosis in breast cancer patients. The expression of IL-10, CD4, CD8, and FOXP3 was detected by immunohistochemistry. Staining intensity of only IL-10 was associated with disease-free survival and distance disease-free survival (P < 0.05). Staining density of IL-10 in stromal cells was associated with overall survival and distance disease-free survival (P < 0.05). IL-10 expression levels might be used as a prognostic indicator for the recurrence, metastasis, and survival of breast cancer patients.
Literature
1.
2.
Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res. 1999;5:189–96.PubMed
3.
Nishimura Y, Taguchi M, Nagai T, Fujihara M, Honda S, Uenishi M. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. Clin Ophthalmol. 2012;6:365–8.PubMedCentralPubMed
4.
5.
Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29:569–79.PubMedCrossRef
6.
Hamidullah A, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133:11–21.PubMedCrossRef
7.
Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102.PubMedCrossRef
8.
Kundu N, Dorsey R, Jackson MJ, Guiterrez P, Wilson K, Fu S, et al. Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer. 1998;76:713–9.PubMedCrossRef
9.
Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21:331–44.PubMedCrossRef
10.
Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, et al. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res. 2013;19:4092–103.PubMedCrossRef
11.
Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macularoedema: a systematic review. Br J Ophthalmol. 2012;96:167–78.PubMedCrossRef
12.
Rao VS, Alabi A, Dyer CE, Greenman J, Drew PJ. IL-10 and IL-12 expression in breast cancer patients and effect of therapy—ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol. 2008;26:14016.
13.
Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007;9:R15.PubMedCentralPubMedCrossRef
14.
Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 2012;72:420–9.PubMedCentralPubMedCrossRef
15.
Kozowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82–4.
16.
Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012;5:110.PubMedCentralPubMedCrossRef
17.
Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29:2445–51.PubMed
18.
Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012;5:11.CrossRef
19.
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55.PubMedCrossRef
20.
Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.PubMedCentralPubMedCrossRef
Metadata
Title
Relationship between IL-10 expression and prognosis in patients with primary breast cancer
Authors
Ying Li
Ping Gao
Junlan Yang
Haiming Yu
Yanyun Zhu
Wen Si
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2249-6

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue

Research Article

High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer

Research Article

Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer

Research Article

Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy

Research Article

SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer

Research Article

Fenofibrate enhances radiosensitivity of esophageal squamous cell carcinoma by suppressing hypoxia-inducible factor-1α expression

Research Article

Long non-coding RNA CARLo-5 is a negative prognostic factor and exhibits tumor pro-oncogenic activity in non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits